SAN DIEGO–(BUSINESS WIRE)–AvantGen, Inc., a biotechnology company with its array of technology platforms for antibody discovery, optimization, and novel NK cell engager generation, today announced Mark F. Kubik has joined AvantGen as Chief Business Officer (CBO). Mark will lead AvantGen’s business development team, developing and managing new business opportunities and strategic partnerships in therapeutic antibody development based on AvantGen’s cutting-edge platforms. Mark has over 25 years of experience in business development, alliance and portfolio management and drug discovery and development. The bulk of this work has focused around successfully leading transformative deal creation and productive alliances in the therapeutic monoclonal



This content is restricted to site members. If you are an existing user, please log in. New users may register too.